PA
NPCE icon

PharVision Advisers’s Neuropace NPCE Stock Holding History

PharVision Advisers’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,699
Closed -$181K – 469
2025
Q4 		$181K Sell
11,699
-10,757
-48% -$144K 0.09% 589
2025
Q3 		$232K Buy
+22,456
New +$212K 0.13% 388

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

PharVision Advisers's NPCE Position: Q1 2026 in Review

PharVision Advisers sold out of Neuropace (NPCE) in Q1 2026, closing a stake of 11,699 shares — an estimated $181K sold.

PharVision Advisers first reported a position in NPCE in Q3 2025 and held it in 2 quarters. The position peaked at $232K in Q3 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • PharVision Advisers reported no remaining Neuropace position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 11,699 Neuropace shares in Q1 2026, an estimated $181K.
  • PharVision Advisers first reported a position in Neuropace in Q3 2025 and held it in 2 quarters.
  • PharVision Advisers's Neuropace position peaked at $232K in Q3 2025.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.